Serum protein profiles differ with adalimumab and ustekinumab treatment in moderately to severely active Crohn’s disease
Although patients receiving either adalimumab or ustekinumab reached similar rates of clinical remission at Week 52, the two therapies resulted in unique serum proteomic expression profiles, reflecting mechanistic differences. Long-term treatment data are necessary to understand how differences in therapeutic mechanisms are associated with maintenance of remission and changes in patient-reported outcomes in the context of inflammatory biomarkers.
Authors
- Bruce E. Sands (ORCID: https://orcid.org/0000-0001-5762-5042)
- Shinichiro Shinzaki (ORCID: https://orcid.org/0000-0002-7051-618X)
- David A. Galbraith (ORCID: https://orcid.org/0000-0003-3457-1269)
- Vipul Jairath (ORCID: https://orcid.org/0000-0002-1092-0033)
- Remo Panaccione
- Martha Zeeman (ORCID: https://orcid.org/0000-0001-6904-021X)
- Tom C. Freeman (ORCID: https://orcid.org/0000-0001-5235-8483)
- Swati Venkat (ORCID: https://orcid.org/0000-0001-7551-3888)
- Patrick Branigan (ORCID: https://orcid.org/0000-0001-9741-9067)
- Sunita Bhagat (ORCID: https://orcid.org/0000-0002-7597-1085)
- James Izanec (ORCID: https://orcid.org/0009-0004-3512-6786)
- Bradford Mcrae
- Paul J. Ufberg
- Amy Hart
- Timothy Hoops
Institutions
- Johnson & Johnson (United States) (US)
- Bristol-Myers Squibb (Germany) (DE)
- University of Calgary (CA)
- University Hospital (CA)
- Bristol-Myers Squibb (Sweden) (SE)
- Hyogo University (JP)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Journal of Crohn s and Colitis
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1093/ecco-jcc/jjaf197
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00